| 2026-08-05 |
AriBio Co., Ltd. |
[Aug 03, 2026]AriBio Completes Treatment Phase of Global Phase 3 POLARIS-AD Trial of AR1001 for Early Alzheimer’s Disease aribiogroup.com ↗ |
| 2026-07-01 |
AriBio Co., Ltd. |
[Jun 30, 2026]AriBio Announces Completion of Dosing in POLARIS-AD Global Phase 3 Trial of AR1001 for Early Alzheimer’s Disease aribiogroup.com ↗ |
| 2026-05-14 |
AriBio Co., Ltd. |
[May 14, 2026]Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer’s Disease aribiogroup.com ↗ |
| 2026-05-13 |
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer’s Disease fosunpharma.com ↗ |
| 2026-04-03 |
AriBio Co., Ltd. |
[Apr 2, 2026] AriBio Appoints Soo Hyun Sung as Co-CEO: “Accelerating the Successful Commercialization of AR1001, the First Oral Disease-Modifying Alzheimer’s Treatment” aribiogroup.com ↗ |
| 2025-08-05 |
AriBio Co., Ltd. |
[Aug 1, 2025]AriBio Showcases AR1001 Alzheimer’s Research at AAIC 2025 aribiogroup.com ↗ |
| 2025-07-29 |
AriBio Co., Ltd. |
[July 29, 2025]Neuco United and Fosun Pharma Sign Exclusive Licensing Agreement for AR1001 in China aribiogroup.com ↗ |
| 2025-07-28 |
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
Neuco United and Fosun Pharma Sign Exclusive Licensing Agreement for AR1001 in China fosunpharma.com ↗ |
| 2025-06-12 |
AriBio Co., Ltd. |
[Jun 12, 2025]AriBio, Attends BIO USA 2025, Pursues Major Deal for Alzheimer’s Treatment ‘AR1001’ aribiogroup.com ↗ |
| 2025-05-28 |
AriBio Co., Ltd. |
[May 28, 2025]ARIBIO Publishes CAA Efficacy of AR1001 in International Journal Oral Drug AR1001 Overcomes Limits of Injectable Alzheimer’s Therapies aribiogroup.com ↗ |
| 2024-05-20 |
AriBio Co., Ltd. |
[Apr 28, 2024]AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD) aribiogroup.com ↗ |
| 2024-05-20 |
AriBio Co., Ltd. |
[Mar 24, 2024]AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for $770 Million USD aribiogroup.com ↗ |
| 2024-05-20 |
AriBio Co., Ltd. |
[Mar 31, 2023]AriBio Co., Ltd. presenteert biomarkergegevens voor AR1001 van de milde tot matige Fase 2-studie aribiogroup.com ↗ |
| 2023-11-01 |
Samjin Pharmaceutical Co., Ltd. |
삼진제약-아리바이오 다중기전 경구용 치매치료제 AR1001 한국 임상3상 전문가 미팅 성료 samjinpharm.co.kr ↗ |
| 2021-12-20 |
AriBio Co., Ltd. |
[AP News]The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Disease, Confirmed in a Recent Independent Study aribiogroup.com ↗ |
| 2021-12-20 |
AriBio Co., Ltd. |
[AP News]The Potential of PDE5 Inhibitors, Such as AriBio’s AR1001, the Lead Clinical Candidate for Alzheimer’s Disease, Confirmed in a Recent Independent Study aribiogroup.com ↗ |
|